SCHEMBL5482836

SCHEMBL5482836

CC(=O)Oc1ccc(C2(c3ccc(OC(C)=O)cc3)C(=O)Nc3c2ccc(Cl)c3OC(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
CNR1 P21554 1/20 0.34
HTT P42858 1/20 0.34
GPR35 Q9HC97 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
TGM2 P21980 1/20 0.33
LMNA P02545 1/20 0.32
FAAH O00519 1/20 0.31
EPHX2 P34913 1/20 0.31
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
MMP8 P22894 1/20 0.31
HCRTR1 O43613 2/20 0.31
HCRTR2 O43614 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
OTUD7B Q6GQQ9 1/20 0.30
ERG P11308 1/20 0.30
ETV1 P50549 1/20 0.30
FLI1 Q01543 1/20 0.30
EWSR1 Q01844 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5475385 0.86 MAPT (0.36) MAPTCNR1HTTGPR35GPR55
SCHEMBL5485534 0.84 CNR1 (0.47) CNR1HTTGPR35GPR55MMP2
SCHEMBL5482094 0.82 MAPT (0.49) MAPTCNR1HTTGPR35GPR55
SCHEMBL5482053 0.82 MAPT (0.56) MAPTCNR1HTTGPR35GPR55
SCHEMBL5478229 0.77 MAPT (0.54) MAPTCNR1HTTGPR35GPR55
SCHEMBL22076805 0.75 CNR1 (0.48) MAPTCNR1HTTGPR35GPR55
SCHEMBL22111806 0.75 CNR1 (0.48) MAPTCNR1HTTGPR35GPR55
SCHEMBL22111762 0.75 CNR1 (0.48) MAPTCNR1HTTGPR35GPR55
SCHEMBL5474601 0.73 MAPT (0.49) MAPTCNR1HTTGPR35GPR55
SCHEMBL5475108 0.72 MAPT (0.47) MAPTCNR1HTTGPR35GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MAPT 1785/4885CNR1 973/4885HTT 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.